Breakthrough therapy is a designation granted by the FDA to expedite the development and review of drugs intended to treat serious or life-threatening conditions. This designation is awarded when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.